| Title |
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, April 2003
|
| DOI | 10.1007/s00259-003-1130-4 |
| Pubmed ID | |
| Authors |
Farrokh Dehdashti, Mark A. Mintun, Jason S. Lewis, Jeffrey Bradley, Ramaswamy Govindan, Richard Laforest, Michael J. Welch, Barry A. Siegel |
| Abstract |
Tumor hypoxia is recognized as an important determinant of response to therapy. In this study we investigated the feasibility of clinical imaging with copper-60 diacetyl-bis( N(4)-methylthiosemicarbazone) ((60)Cu-ATSM) in patients with non-small-cell lung cancer (NSCLC) and also assessed whether pretreatment tumor uptake of (60)Cu-ATSM predicts tumor responsiveness to therapy. Nineteen patients with biopsy-proved NSCLC were studied by positron emission tomography (PET) with (60)Cu-ATSM before initiation of therapy. (60)Cu-ATSM uptake was evaluated semiquantitatively by determining the tumor-to-muscle activity ratio (T/M). All patients also underwent PET with fluorine-18 fluorodeoxyglucose (FDG) prior to institution of therapy. The PET results were correlated with follow-up evaluation (2-46 months). It was demonstrated that PET imaging with (60)Cu-ATSM in patients with NCSLC is feasible. The tumor of one patient had no discernible (60)Cu-ATSM uptake, whereas the tumor uptake in the remaining patients was variable, as expected. Response was evaluated in 14 patients; the mean T/M for (60)Cu-ATSM was significantly lower in responders (1.5+/-0.4) than in nonresponders (3.4+/-0.8) (P=0.002). However, the mean SUV for (60)Cu-ATSM was not significantly different in responders (2.8+/-1.1) and nonresponders (3.5+/-1.0) ( P=0.2). An arbitrarily selected T/M threshold of 3.0 discriminated those likely to respond to therapy: all eight responders had a T/M <3.0 and all six nonresponders had a T/M > or =3.0. Tumor SUV for FDG was not significantly different in responders and nonresponders (P=0.7) and did not correlate with (60)Cu-ATSM uptake (r=0.04; P=0.9). (60)Cu-ATSM-PET can be readily performed in patients with NSCLC and the tumor uptake of (60)Cu-ATSM reveals clinically unique information about tumor oxygenation that is predictive of tumor response to therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Canada | 1 | 1% |
| Denmark | 1 | 1% |
| Belgium | 1 | 1% |
| Japan | 1 | 1% |
| Spain | 1 | 1% |
| Unknown | 74 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 20 | 25% |
| Researcher | 16 | 20% |
| Other | 7 | 9% |
| Student > Doctoral Student | 6 | 7% |
| Professor | 4 | 5% |
| Other | 17 | 21% |
| Unknown | 11 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 37% |
| Chemistry | 8 | 10% |
| Physics and Astronomy | 7 | 9% |
| Agricultural and Biological Sciences | 6 | 7% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Other | 11 | 14% |
| Unknown | 14 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2020.
All research outputs
#3,463,623
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#382
of 3,083 outputs
Outputs of similar age
#5,028
of 51,510 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#1
of 13 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 51,510 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.